CPDC and McMaster Nuclear Reactor Sign Research Agreement for Production of High Value Medical Isotopes

​

The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, and the McMaster Nuclear Reactor facility (MNR), a leading research reactor program that provides a source of medical radioisotopes, announced that they have signed an agreement to explore the development of processes to produce rare and high-value medical radioisotopes utilizing the nuclear reactor at McMaster University in Hamilton, Ontario and CPDC’s GMP production capabilities. The companies have signed a Memorandum of Understanding to explore the production and processing of important radioisotopes that are increasing in clinical utility but are in limited supply.

To read more please visit: https://business.financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/cpdc-and-mcmaster-nuclear-reactor-sign-research-agreement-for-production-of-high-value-medical-isotopes

Source: Financial Post